Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIASTAT vs BANZEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.
BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.
Status epilepticus (FDA-approved for acute management),Breakthrough seizures in patients on stable antiepileptic regimen (FDA-approved),Preoperative anxiety (off-label),Alcohol withdrawal syndrome (off-label),Muscle spasm (off-label)
Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 1 year of age and older (FDA-approved),Off-label: Adjunctive therapy for partial-onset seizures, generalized tonic-clonic seizures, and other refractory epilepsies
Adult: 0.2 mg/kg (max 20 mg) rectally as a single dose; may repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.
400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.
30–60 hours for diazepam; nordazepam (active metabolite) 50–120 hours. Prolonged in elderly, liver disease, and neonates
Terminal elimination half-life is approximately 6-10 hours in adults; in pediatric patients, it is shorter (~3-6 hours). Steady-state is reached within 1-2 days.
Primarily hepatic via CYP2C19 and CYP3A4; active metabolite desmethyldiazepam (with long half-life); minor pathways include glucuronidation.
Primarily hydrolyzed by carboxylesterases in the liver to inactive metabolites (CGP 47292). Minor metabolism via CYP450 enzymes (CYP2E1, CYP3A4, CYP1A2, CYP2B6, CYP2C9, CYP2C19) but not significantly.
Renal (primarily as glucuronide and sulfate conjugates; <5% unchanged), biliary/fecal minimal
Primarily renal: approximately 66% of the dose excreted in urine (30% as unchanged rufinamide, 70% as inactive metabolites). Fecal excretion: ~4%. No significant biliary excretion.
98–99%; primarily albumin
Approximately 34% bound to plasma proteins, primarily albumin.
0.8–1.0 L/kg; increased in obesity (1.5–2.5 L/kg), redistribution to adipose tissue prolongs half-life
Apparent volume of distribution is approximately 0.7-1.0 L/kg, indicating distribution primarily into total body water.
Rectal: 90% (relative to IV, complete absorption). Oral: 100%
Absolute oral bioavailability is approximately 85% (high). Food increases Cmax and AUC by about 30-40%, but this is not considered clinically significant for dosing.
No specific dose adjustment required for renal impairment; however, use with caution in severe impairment (Cr Cl <10 m L/min) due to prolonged half-life.
Cr Cl < 30 m L/min: not recommended. Cr Cl 30-50 m L/min: maximum dose 400 mg twice daily. Cr Cl > 50 m L/min: no adjustment.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Reduce dose by 75% or avoid use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: start 200 mg twice daily, maximum 400 mg twice daily. Child-Pugh Class C: not recommended.
Children 2-5 years: 0.5 mg/kg (max 20 mg) rectally. Children 6-11 years: 0.3 mg/kg (max 20 mg) rectally. Children 12+ years: same as adult dosing. May repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.
Age ≥4 years: based on body weight. Starting dose: 10 mg/kg/day divided twice daily, titrate weekly by increments of 10 mg/kg/day to target maintenance 40 mg/kg/day (max 3200 mg/day). Max single dose: 1600 mg twice daily.
Initiate at lower end of dosing range (e.g., 0.1-0.15 mg/kg, max 10 mg) due to increased sensitivity and risk of falls; monitor for prolonged sedation and respiratory depression.
No specific dose adjustment, but consider age-related renal impairment; monitor Cr Cl.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.
None
Risk of respiratory depression, especially with concomitant CNS depressants; tolerance and physical dependence may develop; withdrawal symptoms including seizures after abrupt discontinuation; caution in elderly, debilitated patients, and those with hepatic impairment; may cause drowsiness or dizziness; not recommended for use in pregnancy (neonatal withdrawal).
May shorten QT interval; use caution with other drugs that shorten QT interval. Increased risk of suicidal thoughts/behavior. Monitor for hypersensitivity reactions (including DRESS). Central nervous system depression (dizziness, somnolence, ataxia). May decrease efficacy of hormonal contraceptives. Withdrawal seizures if abruptly discontinued. Dose adjustment needed in severe hepatic impairment.
Known hypersensitivity to diazepam or any benzodiazepine; myasthenia gravis; severe respiratory insufficiency; severe hepatic insufficiency; sleep apnea syndrome; narrow-angle glaucoma (in patients receiving anticholinergic therapy).
Familial short QT syndrome (due to QT interval shortening). Hypersensitivity to rufinamide or any of its components.
No specific food interactions. Avoid grapefruit juice as it may increase diazepam levels. Alcohol can potentiate CNS depression.
BANZEL should be taken with food to increase bioavailability (Cmax increases by approximately 40% and AUC by 50% compared to fasting). Avoid grapefruit juice as it may alter drug metabolism. No other food interactions are documented.
DIASTAT (diazepam) is classified as Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip and palate, when used during the first trimester. Second and third trimesters: Chronic use may lead to fetal dependence and withdrawal symptoms postnatally; risk of floppy infant syndrome (hypotonia, lethargy, sucking difficulties) when administered near term.
First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of intrauterine growth restriction, neurodevelopmental delay, and hemorrhagic disease of the newborn due to vitamin K deficiency.
Diazepam is excreted into breast milk with an M/P ratio of approximately 0.2-0.5. The American Academy of Pediatrics recommends use with caution due to potential accumulation and sedation in the infant. Avoid chronic use; if necessary, monitor infant for sedation, poor feeding, and weight gain.
Rufinamide is excreted in human milk. The milk-to-plasma ratio is approximately 0.3. Breastfeeding is not recommended due to potential adverse effects in the infant, including somnolence, poor feeding, and weight loss.
Due to increased volume of distribution and altered protein binding in pregnancy, total clearance of diazepam may be increased, potentially requiring higher doses to achieve therapeutic effect. However, routine dose adjustment is not recommended without clinical monitoring. Use lowest effective dose for shortest duration. Caution in third trimester due to increased risk of neonatal effects.
Pregnancy may reduce serum concentrations due to increased clearance and volume of distribution. Monitor trough levels and adjust dose to maintain therapeutic efficacy. Postpartum, monitor for toxicity as levels may rise.
DIASTAT (diazepam rectal gel) is a formulation for acute management of seizure clusters. Administer rectally; monitor for respiratory depression, especially with concomitant CNS depressants. Do not exceed 5 doses per month or use for more than 5 episodes per month due to tolerance risk. Have flumazenil available for reversal.
BANZEL (rufinamide) is an antiepileptic drug indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients ≥1 year. Titrate slowly over 2-3 weeks to reduce risk of adverse effects. Monitor for shortened QT interval; contraindicated in familial short QT syndrome. Dose adjustments needed in severe hepatic impairment. May decrease efficacy of oral contraceptives containing ethinyl estradiol. Administer with food to enhance absorption.
Use only as directed for episodes of increased seizure activity.,Administer rectally; do not reuse diapers/suppositories.,Monitor for drowsiness, dizziness, or breathing problems.,Avoid alcohol and other CNS depressants.,Store at room temperature; protect from light.,Seek emergency care if seizures last longer than usual or breathing is difficult.
Take BANZEL exactly as prescribed with food to improve absorption.,Do not stop taking BANZEL suddenly; taper under medical supervision to avoid withdrawal seizures.,Inform your doctor if you have a heart condition, especially short QT syndrome.,Use effective contraception if applicable; BANZEL may reduce efficacy of oral contraceptives.,Monitor for dizziness, drowsiness, or coordination problems; avoid driving until you know how BANZEL affects you.,Report any unusual tiredness, fatigue, or signs of liver injury (yellowing skin/eyes, dark urine) immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIASTAT vs BANZEL, answered by our medical review team.
DIASTAT is a Benzodiazepine Anticonvulsant that works by Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.. BANZEL is a Anticonvulsant that works by BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIASTAT and BANZEL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIASTAT is: Adult: 0.2 mg/kg (max 20 mg) rectally as a single dose; may repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.. The standard adult dose of BANZEL is: 400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIASTAT and BANZEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIASTAT is classified as Category C. DIASTAT (diazepam) is classified as Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip and palate, when used during the first. BANZEL is classified as Category C. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.